Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Praxis faces FDA delay, analysts point finger at agency layoffs
TD Cowen analysts said they “strongly believe FDA bandwidth constraints from last year’s agency downsizing likely contributed to the delay.”
Nick Paul Taylor
Jun 30, 2026 4:13am
BioCryst ends internal programs in pivot to partnerships
Jun 29, 2026 10:30am
AstraZeneca posts phase 3 bone disease data on Strensiq heir
Jun 29, 2026 4:51am
Ionis bags $30M from Recordati for ex-US rare disease rights
Jun 25, 2026 6:59am
Serapha takes flight with $230M, gene-editing prospect from China
Jun 23, 2026 1:55pm
Merck KGaA pledges $50M to new biotech with eye to acquisition
Jun 23, 2026 10:16am
